Earnings summaries and quarterly performance for UFP TECHNOLOGIES.
Executive leadership at UFP TECHNOLOGIES.
R. Jeffrey Bailly
Detailed
Chief Executive Officer
CEO
CP
Christopher P. Litterio
Detailed
General Counsel, Secretary, and Senior Vice President of Human Resources
JH
Jason Holt
Detailed
Vice President and Chief Commercial Officer
MC
Mitchell C. Rock
Detailed
President
RJ
Ronald J. Lataille
Detailed
Senior Vice President, Treasurer, and Chief Financial Officer
Board of directors at UFP TECHNOLOGIES.
Research analysts who have asked questions during UFP TECHNOLOGIES earnings calls.
Andrew Cooper
Raymond James
6 questions for UFPT
Also covers: AZTA, CDNA, CTKB +12 more
Justin Ages
CJS Securities
6 questions for UFPT
Also covers: CR, CVCO, DBD +4 more
Brett Fishbin
KeyBanc Capital Markets
4 questions for UFPT
Also covers: ALC, COO, ICUI +7 more
Jaeson Schmidt
Lake Street Capital Markets
4 questions for UFPT
Also covers: AIRG, AVNW, BHE +15 more
MM
Max Michaelis
Lake Street Capital
2 questions for UFPT
Also covers: ALNT, BHE, DHX +7 more
W
Will
CJS Securities
1 question for UFPT
Also covers: DLX, HLIO, INDI
Recent press releases and 8-K filings for UFPT.
UFP Technologies Highlights Strong Growth, Strategic Acquisitions, and Key Customer Contract Extension
UFPT
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- UFP Technologies (UFPT), a MedTech contract development and manufacturing organization (CDMO), reported approximately $600 million in revenue, serving 26 of the top 30 med device companies.
- The company has experienced substantial growth, tripling revenue and increasing medical sales 4x over the past four years, with bottom line figures also rising 400%.
- Key growth drivers include Robotic Assisted Surgery (28%-29% of business) and the rapidly expanding Safe Patient Handling market, bolstered by the mid-2024 acquisition of AJR.
- UFPT aims for 12%-18% revenue growth (half internal, half acquisition) and targets 28%-31% gross margins and 17%-20% adjusted operating margins.
- A recent extension and expansion of a contract with a major customer has increased minimums and added a new program, mitigating prior concerns about customer concentration.
Mar 3, 2026, 7:50 PM
UFP Technologies Presents Growth Strategy and Financial Performance
UFPT
Revenue Acceleration/Inflection
M&A
New Projects/Investments
- UFP Technologies, a medical device contract development and manufacturing organization (CDMO), reported approximately $600 million in revenue and has achieved substantial growth, tripling overall revenue and increasing medical sales by 4x in the last four years, with bottom line figures also up 400%.
- The company's growth is driven by a two-pronged strategy of internal expansion into high-margin segments and strategic acquisitions, exemplified by DAS Medical's revenue growing from $40M-$50M to $150M and AJR's from $75M to $130M+ post-acquisition.
- Recent developments include the extension and expansion of a contract with a major customer, which now includes increased minimums and a new program, addressing prior market concerns.
- UFP Technologies targets annual revenue growth of 12%-18%, gross margins of 28%-31%, and adjusted operating margins of 17%-20%, supported by strong positions in rapidly growing markets such as robotic surgery (28-29% of business) and patient safety.
- The company plans strategic expansion into the APAC region within the next 12-18 months, with customer investment, to further support its growth objectives.
Mar 3, 2026, 7:50 PM
UFP Technologies Discusses Growth Strategy, Financial Targets, and Key Customer Contract Extension
UFPT
M&A
Revenue Acceleration/Inflection
Guidance Update
- UFP Technologies, a medical device contract development and manufacturing organization (CDMO) with approximately $600 million in revenue, outlined a two-pronged growth strategy combining internal expansion and strategic acquisitions.
- The company reported significant historical growth, tripling revenue and quadrupling medical sales over the past four years, with bottom-line figures increasing by 400%. Future financial targets include 12%-18% revenue growth, 28%-31% gross margins, and 17%-20% adjusted operating margins.
- A major customer contract was recently extended and expanded, including increased minimums and a new program, which addresses previous concerns about customer retention. Key growth areas include robotic drapes (28%-29% of business) and safe patient handling (second-largest market, double-digit growth), supported by successful acquisitions like DAS Medical and AJR.
Mar 3, 2026, 7:50 PM
UFP Technologies Outlines MedTech Growth and Financial Targets
UFPT
Guidance Update
M&A
Revenue Acceleration/Inflection
- UFP Technologies (UFPT) presented an investor update in March 2026, detailing its strategic shift and growth in the MedTech sector.
- The company reported significant growth in MedTech sales, which increased from $132 million in 2021 to $555 million in 2025, contributing to total company sales of $600 million in 2025.
- UFPT has established 3 to 5 year financial targets, including 12-18% revenue growth, 28-31% gross margin, and 17-20% adjusted operating margin.
- The company's growth strategy is two-pronged, focusing on internal expansion within high-growth MedTech segments like robotic surgery, and strategic acquisitions to enhance capabilities and scale.
- As of December 2025, MedTech revenue was primarily driven by Devices (55%), Robotic Assisted Surgery (RAS) (28%), and Packaging (17%).
Mar 2, 2026, 12:00 PM
UFP Technologies Reports Strong 2025 Results, Strategic Progress, and CEO Transition
UFPT
Earnings
New Projects/Investments
CEO Change
- UFP Technologies reported full-year 2025 sales growth of 19.5% to $602.8 million, with operating income growing 435% and EPS growing 419% since 2021, and 2025 EPS growing 15.4%.
- The company made significant progress on strategic initiatives, including expanding capabilities and launching new programs in the Dominican Republic, and addressed $6.3 million in labor inefficiencies at its Illinois AJR facility in 2025, with Q4 impact significantly reduced and further improvement expected.
- UFP Technologies expanded and extended its contract with its largest customer, materially increasing volumes and adding a new program, and secured a contract extension with its largest infection prevention customer through 2030. A cybersecurity breach in February 2026 caused minimal operational interruption and is not expected to have a material financial impact.
- The CEO transition planning is complete, with Mitch Rock set to succeed Jeff Bailly as CEO in June 2026.
Feb 25, 2026, 1:30 PM
UFP Technologies Reports Strong 2025 Results and Strategic Progress
UFPT
Earnings
New Projects/Investments
CEO Change
- UFP Technologies reported strong 2025 financial results, with sales growing 19.5% to $602.8 million for the full year, and EPS increasing 15.4% despite absorbing $6.3 million in labor inefficiencies.
- The company made significant strategic progress, including expanding capabilities in the Dominican Republic, extending contracts with its largest customers, and successfully integrating seven acquisitions from 2024-2025.
- A cybersecurity breach was detected on February 14, 2026, but caused minimal operational interruptions, with primary systems back online and no material financial impact expected due to insurance and contingency plans.
- UFP Technologies generated $92 million in cash from operations in 2025 and paid down $53.9 million in debt, ending the year with a leverage ratio of approximately 1.1 times.
- The CEO transition planning is complete, with the new CEO scheduled to succeed in June 2026, and the current CEO will continue as executive chair for one year.
Feb 25, 2026, 1:30 PM
UFP Technologies Extends and Expands Supply Agreement with Strategic Medical Customer
UFPT
New Projects/Investments
Revenue Acceleration/Inflection
- UFP Technologies, Inc. (UFP), through a wholly-owned subsidiary, entered into Amendment No. 27 to its Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical SARL on February 19, 2026, effective January 1, 2026.
- The amendment extends the term of the Supply Agreement by two additional years through December 31, 2029.
- It also materially increases the annual minimum volumes for the largest program for 2028 and 2029 and adds an additional program to the agreement.
- The agreement now includes volume-based pricing based on certain minimum purchase thresholds and cost-sharing provisions.
Feb 24, 2026, 9:41 PM
UFPT Announces Record 2025 Results
UFPT
Earnings
Revenue Acceleration/Inflection
M&A
- UFP Technologies reported record net sales of $602.8 million for the year ended December 31, 2025, an increase of 19.5% over 2024, with net income rising 15.8% to $68.3 million and GAAP EPS reaching $8.75.
- This growth was primarily fueled by a 23.2% increase in medical sales for 2025, despite an 11.5% decrease in non-medical sales.
- The company absorbed approximately $6.3 million in labor-related inefficiencies at its AJR facility in Illinois during 2025, though the impact in Q4 2025 dropped to $1.2 million.
- Strategic initiatives included expanding businesses in the Dominican Republic, securing a contract extension with its largest customer through 2029, and successfully integrating seven acquisitions completed in 2024 and 2025.
- For the fourth quarter of 2025, net sales increased 3.4% to $148.9 million, and GAAP EPS was $2.25.
Feb 24, 2026, 9:39 PM
UFP Technologies Announces Record 2025 Results
UFPT
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- UFP Technologies reported record 2025 net sales of $602.8 million, a 19.5% increase over 2024, primarily driven by a 23.2% rise in medical sales.
- Net income for 2025 increased 15.8% to $68.3 million, with GAAP earnings per diluted share reaching $8.75, up 15.4% year-over-year.
- The company made significant progress on strategic initiatives, including expanding operations in the Dominican Republic with new facilities and programs, and successfully integrating seven acquisitions from 2024 and 2025.
- Despite absorbing approximately $6.3 million in labor-related inefficiencies at its Illinois facility in 2025, the company achieved strong earnings growth.
Feb 24, 2026, 9:30 PM
UFP Technologies Highlights Strong Medtech Growth and Announces CEO Succession
UFPT
Revenue Acceleration/Inflection
Management Change
M&A
- UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient Medtech devices, with current revenue of approximately $600 million. The company has seen its Medtech revenue grow 3x from $132 million in 2021 to $550 million today.
- The company targets annual revenue growth of 12%-18% (half from acquisitions, half internal), gross margins of 28%-31%, and adjusted operating margins of 17%-20%.
- Jeff Bailly, Chairman and CEO, announced his retirement in June next year, with Mitch Rock, the current President, slated to become the new CEO.
- An acquisition, AJR, is experiencing challenges as more than half of its employees were found to be illegal to work in the U.S., requiring replacement and training, which is expected to impact results for a couple more quarters.
Dec 3, 2025, 1:10 PM
Quarterly earnings call transcripts for UFP TECHNOLOGIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more